[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"breast-augmentation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:breast-augmentation":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,83,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100645162","a-post-market-prospective-clinical-study-of-eurosilicone-luna-mammary-implants-100645162",false,"NCT07679594","A Post-market Prospective Clinical Study of Eurosilicone Luna Mammary Implants","A Prospective, Multi-centre, Observational, Non-comparative, Post-marketing Surveillance Study to Obtain Clinical Outcome Data on the Eurosilicone LunaXT Range of Silicone Breast Implants When Used in Breast Implantation.","Inclusion Criteria:\n\n* The target population includes subjects undergoing augmentation or reconstructive breast implant surgery in which the Eurosilicone Luna mammary implant is recommended.\n\nInclusion criteria are:\n\n1. Genetic female subjects aged between 18 and 65 years old.\n2. Subjects who underwent single or bilateral breast implantation with the study device for one of the following reasons:\n\ni. Primary breast reconstruction following mastectomy (both for one-stage or two-stage surgeries, including patients with previous radiotherapy and who have ADMs (synthetic or natural).\n\nii. Primary breast augmentation (cosmetic surgery) with or without mastopexy iii. Breast revision surgery with or without mastopexy c) Subjects who have received a Eurosilicone Luna implant. d) Subjects who have provided informed consent and can adhere to the requirements of follow-up appointments as per the study protocol.\n\nExclusion criteria are:\n\n1. Subjects with a BMI \\>35.\n2. Subjects with autoimmune disease, lung fibrocystic disease, conditions that interfere with wound healing and blood clotting, a weakened immune system, reduced blood supply to the breast tissue or any other condition for which breast implants are contraindicated.\n3. Subjects who have participated in a clinical study which involve chemical or drug study within 3 months prior to surgery, with the exception of subjects who are participating in breast cancer-related clinical studies.\n4. Subjects with insufficient tissue covering due to either radiation damage on the chest wall, tight thoracic skin grafts or radical resection of the pectoralis major muscle.\n5. Subjects who, in the Investigator's clinical opinion, have existing local or metastatic carcinoma of the breast that is unlikely to be fully excised at the time of insertion of the breast implant.\n6. Subjects with known previous history of a sensitivity to silicone who, in the opinion of the Investigator, are unsuitable for surgery.\n7. Subjects with an active infection who are unsuitable for surgery unless, in the opinion of the investigator, they are treated and cleared by the investigator.\n8. Subjects with a history of abscesses anywhere in the body who, in the opinion of the Investigator, are unsuitable for surgery.\n9. Subjects with a known history of compromised wound healing.\n10. Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study.\n11. Women who are pregnant and\u002For current breast feeders who do not stop breast feeding within 3 months of getting breast implants.\n12. Patients who have local recurrence or metastatic carcinoma at the time of insertion of breast implant.",true,"FEMALE","18 Years","65 Years",{"count":21,"type":22},650,"ESTIMATED","OBSERVATIONAL","The goal of this observational, non-comparative study is to determine the frequency and rate of rupture and capsular contracture Baker III-IV of Eurosilicone Luna range of breast implants, over a 10-year period following surgical implantation in female population between 18 and 65 years old undergoing primary or revision of breast augmentation or breast reconstruction.",[26,27,28,29,30,31],"Breast Augmentation","Breast Reconstruction","Breast Revision-Augmentation","Breast Reconstruction With Silicone Implants","Breast Reconstruction, Revision Breast Reconstruction","Breast Augmentation and Breast Reconstruction",[33,34,35],"Luna XT","Anatomical breast implant","Mammary implant","RECRUITING","2026-06-25",{"date":39,"type":40},"2026-07-01","ACTUAL",{"date":42,"type":40},"2026-03-30",{"date":44,"type":22},"2038-12-31",{"name":46,"class":47},"GCA (Eurosilicone)","INDUSTRY",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":59,"conditions":60,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},"100517128","post-market-prospective-clinical-study-of-nagor-perle-mammary-implants-100517128","NCT06013514","Post-market Prospective Clinical Study of Nagor Perle Mammary Implants","A Prospective, Multi-center, Observational, Non Comparative, Post-marketing Surveillance Study to Obtain Clinical Outcome Data on the Nagor PERLE Range of Silicone Breast Implants When Used in Breast Implantation","PERLE10PMCF","Inclusion Criteria:\n\n1. Genetic female subjects aged ≥18 and ≤65\n2. Subjects who underwent single or bilateral breast implantation with the study device for one of the following reasons:-\n\ni) Primary breast reconstruction following mastectomy (both for one-stage or two-stage surgeries, including patients with previous radiotherapy and who have ADMs of animal origin (bovine, porcine)). ii) Primary breast augmentation (cosmetic surgery) with or without mastopexy iii) Breast revision surgery with or without mastopexy c) Subjects who have received a Nagor PERLE implant. d) Subjects who have provided informed consent and can adhere to the requirements of follow up appointments as per the study protocol.\n\nExclusion Criteria:\n\n1. Subjects undergoing implant augmentation with a BMI \\> 30 and undergoing reconstruction with a BMI \\>32.\n2. Subjects with autoimmune disease, lung fibrocystic disease, conditions that interfere with wound healing and blood clotting, a weakened immune system, reduced blood supply to the breast tissue or any other condition for which breast implants are contraindicated.\n3. Subjects who have participated in a clinical study which involve chemical or drug study within 3 months prior to surgery, with the exception of subjects who are participating in breast cancer related clinical studies.\n4. Subjects with insufficient tissue covering due to either radiation damage on the chest wall, tight thoracic skin grafts or radical resection of the pectoralis major muscle.\n5. Subjects who have ADMs of synthetic origin.\n6. Subjects who, in the Investigator's clinical opinion, have existing local or metastatic carcinoma of the breast that is unlikely to be fully excised at the time of insertion of the breast implant.\n7. Subjects with known previous history of a sensitivity to silicone who, in the opinion of the Investigator, are unsuitable for surgery.\n8. Subjects with an active infection who are unsuitable for surgery unless, in the opinion of the investigator, they are treated and cleared by the investigator.\n9. Subjects with a history of abscesses anywhere in the body who, in the opinion of the Investigator, are unsuitable for surgery.\n10. Subjects with a known history of compromised wound healing.\n11. Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study.\n12. Women who are pregnant and\u002For current breast feeders who do not stop breast feeding within 3 months of getting breast implants\n13. Patients who have local recurrence or metastatic carcinoma at the time of insertion of breast implant",{"count":58,"type":22},60,"Patients can undergo breast implant surgery for multiple reasons; cosmetic and reconstructive being the primary indications. In order to confidently state safety and due to strict regulation on medical devices it is important to maintain a record of safety and performance with all medical implants.\n\nThis study is designed to collect data on a new generation of smooth mammary implants to assess the long term performance and safety data on this type of gel-filled mammary breast implant.\n\nThe two main complications of breast implants are capsular contracture and rupture; these complications can take years to develop. The study is designed to evaluate the occurrence of these two primary complication as well as other secondary complications over a period of 10 years. Patient follow up will be carried out pre-operatively and post operatively at 12 months and then 3, 5, 8 and 10 years thereafter.\n\nThe study will be carried out over 10 years to adequately assess complications which may only occur over the lifetime of the device such as systemic complications",[27,61,62,26,29,63,64,65],"Breast Reconstruction Following Mastectomy","Breast Revision","Breast Reconstruction After Mastectomy","Breast Reconstruction Surgery","Breast Implants",[67,68,69,70,71,72,73,74],"prospective","observational","non-comparative","post-marketing study","PMCF","Perle","Nagor","GCA",{"date":76,"type":40},"2026-06-29",{"date":78,"type":40},"2024-06-01",{"date":80,"type":22},"2038-09",{"name":46,"class":47},1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100555293","the-study-is-an-observational-post-market-follow-up-program-to-evaluate-long-term-5-years-safety-of-mentor-breast-implants-in-chinese-population-100555293","NCT06510205","The Study is an Observational Post-market Follow-up Program to Evaluate Long Term (5 Years) Safety of Mentor Breast Implants in Chinese Population","MNT202401: Post Market Clinical Follow up for Mentor Breast Implants","Inclusion Criteria:\n\n1. Women who have received Mentor breast implants per product instructions;\n2. Participants must possess the ability to comprehend the study procedures, give consent for the use of their preoperative and surgical data, and agree to take part in postoperative follow-up assessments. Additionally, they should possess the necessary civil capacity, be capable of reading and writing, and willingly provide informed consent by signing the consent form.\n3. Aged not less than 18 years at the time of implantation surgery (for products with registration license Guoxie Zhujin 20223130323, the participant's age should be not less than 22 years).\n\nExclusion Criteria:\n\n* Not applicable","100 Years",{"count":92,"type":22},6111,"The Mentor Post-Market Clinical Follow-Up Study is a multicenter observational study conducted in China. It aims to collect safety data on Mentor breast implants over a 5-year follow-up period in the Chinese population. In addition to safety data, the study will also gather information on postoperative pain and participant satisfaction levels. The objective is to explore customers' clinical experiences and use them as a reference for future product development. The study intends to enroll different number of participants for each license.",[26,95],"Mammaplasty","2026-06-11",{"date":98,"type":40},"2026-06-15",{"date":100,"type":40},"2024-07-14",{"date":102,"type":22},"2034-12-31",{"name":104,"class":47},"Johnson & Johnson Medical (Shanghai) Ltd.",3,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":114,"targetDuration":4,"studyType":116,"phases":117,"briefSummary":119,"conditions":120,"keywords":123,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":82},"100627408","effect-of-bilateral-rhomboid-intercostal-block-on-postoperative-pain-after-breast-implant-surgery-100627408","NCT07448246","Effect of Bilateral Rhomboid Intercostal Block on Postoperative Pain After Breast Implant Surgery","The Effect of Bilateral Rhomboid Intercostal Block on Postoperative Analgesia and Opioid Consumption in Patients Undergoing Bilateral Breast Implant Surgery: A Prospective Controlled Study","RIB-BREAST","Inclusion Criteria:\n\n* Female patients aged 18-65 years\n* American Society of Anesthesiologists (ASA) physical status I-II\n* Scheduled for elective bilateral breast prosthesis surgery\n* Ability to understand the study protocol and provide written informed consent\n\nExclusion Criteria:\n\n* Refusal to participate\n* Known allergy or hypersensitivity to local anesthetics (lidocaine or bupivacaine) or tramadol\n* Coagulation disorders or current anticoagulant therapy\n* Infection at the injection site\n* Chronic opioid use or chronic pain syndromes\n* Severe hepatic, renal, or cardiac disease\n* Neurological or psychiatric conditions interfering with pain assessment\n* Body mass index (BMI) \\> 35 kg\u002Fm²\n* Pregnancy or breastfeeding",{"count":115,"type":22},40,"INTERVENTIONAL",[118],"NA","This prospective, randomized, single-center, study aims to evaluate the postoperative analgesic effectiveness of bilateral Rhomboid Intercostal Block (RIB) in patients undergoing elective bilateral breast prosthesis surgery. Effective postoperative pain management is essential to improve patient comfort and reduce opioid consumption.\n\nEligible patients aged 18-65 years with ASA physical status I-II will be randomly assigned to either receive ultrasound-guided bilateral RIB block in addition to standard general anesthesia or undergo surgery without any regional block (control group). All patients will receive standardized general anesthesia and postoperative patient-controlled analgesia (PCA) with intravenous tramadol.\n\nThe primary outcome of the study is total tramadol consumption within the first 24 postoperative hours. Secondary outcomes include postoperative pain scores at predefined time points, time to first analgesic requirement, need for rescue analgesia, incidence of nausea and vomiting, and block-related complications.\n\nThe results of this study will help determine whether bilateral RIB block provides superior postoperative pain control compared to standard analgesic management alone in bilateral breast prosthesis surgery.",[121,122,26],"Breast Prosthesis; Pain","Postoperative Pain",[124,125,126,127,128,129,130],"Rhomboid Intercostal Block","RIB Block","Regional Anesthesia","Postoperative Analgesia","Breast Surgery","Tramadol PCA","Ultrasound-Guided Block","2026-02-28",{"date":133,"type":40},"2026-03-04",{"date":135,"type":40},"2026-02-15",{"date":137,"type":22},"2027-04-15",{"name":139,"class":140},"Aydin Adnan Menderes University","OTHER"]